Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGW101 in Advanced Solid Tumors
NCT06959706Phase 1Recruiting
- Sponsor
- Tagworks Pharmaceuticals
- Start
- May 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of TGW101 in solid tumor (2 arms), sponsored by Tagworks Pharmaceuticals. Primary endpoints: Number of Participants Experiencing Adverse Events at 10 months, Number of Participants Experiencing Dose-limiting Toxicities at 28 days and 3 more. Started May 2025; status: recruiting.
02
Drugs
TGW101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06959706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959706.